Grand Pharmaceutical Group Future Growth

Future criteria checks 2/6

Grand Pharmaceutical Group is forecast to grow earnings and revenue by 3.3% and 9% per annum respectively. EPS is expected to grow by 2.9% per annum. Return on equity is forecast to be 13.4% in 3 years.

Key information

3.3%

Earnings growth rate

2.91%

EPS growth rate

Pharmaceuticals earnings growth	11.1%
Revenue growth rate	9.0%
Future return on equity	13.38%
Analyst coverage	Low
Last updated	20 May 2025

Recent future growth updates

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

May 12

Grand Pharmaceutical Group Limited's (HKG:512) CEO Compensation Looks Acceptable To Us And Here's Why

Apr 03

Additional Considerations Required While Assessing Grand Pharmaceutical Group's (HKG:512) Strong Earnings

Mar 25

Little Excitement Around Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Feb 24

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

Earnings and Revenue Growth Forecasts

SEHK:512 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	15,223	2,739	2,085	2,990	2
12/31/2026	13,932	2,345	1,252	2,476	5
12/31/2025	12,329	2,156	1,466	2,502	4
12/31/2024	11,645	2,468	1,301	1,898	N/A
9/30/2024	11,116	2,438	1,376	1,900	N/A
6/30/2024	10,587	2,409	1,451	1,903	N/A
3/31/2024	10,558	2,144	1,694	2,164	N/A
12/31/2023	10,530	1,880	1,937	2,425	N/A
9/30/2023	10,434	2,139	1,349	2,114	N/A
6/30/2023	10,339	2,398	761	1,804	N/A
3/31/2023	9,951	2,239	773	1,823	N/A
12/31/2022	9,562	2,079	785	1,843	N/A
9/30/2022	9,403	1,995	1,068	1,829	N/A
6/30/2022	9,244	1,910	1,350	1,815	N/A
3/31/2022	8,921	2,156	1,410	1,911	N/A
12/31/2021	8,598	2,403	1,469	2,006	N/A
9/30/2021	8,131	2,340	1,487	2,001	N/A
6/30/2021	7,664	2,277	1,504	1,995	N/A
3/31/2021	7,008	2,035	1,351	1,726	N/A
12/31/2020	6,353	1,793	1,197	1,456	N/A
9/30/2020	6,306	1,558	1,020	1,400	N/A
6/30/2020	6,259	1,323	843	1,345	N/A
3/31/2020	6,425	1,237	790	1,324	N/A
12/31/2019	6,591	1,151	737	1,304	N/A
9/30/2019	6,450	1,048	1,177	1,661	N/A
6/30/2019	6,309	944	1,618	2,017	N/A
3/31/2019	6,134	828	1,326	1,713	N/A
12/31/2018	5,958	713	1,034	1,408	N/A
9/30/2018	5,845	642	N/A	898	N/A
6/30/2018	5,732	570	N/A	387	N/A
3/31/2018	5,251	516	N/A	553	N/A
12/31/2017	4,771	461	N/A	720	N/A
9/30/2017	4,480	413	N/A	708	N/A
6/30/2017	4,190	364	N/A	696	N/A
3/31/2017	3,943	317	N/A	736	N/A
12/31/2016	3,696	269	N/A	775	N/A
9/30/2016	3,573	241	N/A	807	N/A
6/30/2016	3,450	213	N/A	839	N/A
3/31/2016	3,348	197	N/A	668	N/A
12/31/2015	3,246	181	N/A	496	N/A
9/30/2015	3,158	187	N/A	439	N/A
6/30/2015	3,071	194	N/A	382	N/A
3/31/2015	3,097	185	N/A	430	N/A
12/31/2014	3,122	175	N/A	477	N/A
9/30/2014	3,040	150	N/A	602	N/A
6/30/2014	2,958	126	N/A	728	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 512's forecast earnings growth (3.3% per year) is above the savings rate (2.6%).

Earnings vs Market: 512's earnings (3.3% per year) are forecast to grow slower than the Hong Kong market (10.5% per year).

High Growth Earnings: 512's earnings are forecast to grow, but not significantly.

Revenue vs Market: 512's revenue (9% per year) is forecast to grow faster than the Hong Kong market (8.3% per year).

High Growth Revenue: 512's revenue (9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 512's Return on Equity is forecast to be low in 3 years time (13.4%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/23 11:27
End of Day Share Price	2025/05/23 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grand Pharmaceutical Group Limited is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yanyin Zhu	China International Capital Corporation Limited
Xiao Wei Lin	Everbright Securities Co. Ltd.
Chao Zhang	Guosen Securities Co., Ltd.

Grand Pharmaceutical Group Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 11% to HK$8.03

Price target increased by 9.1% to HK$7.23

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Recent updates

Executive Chairman recently bought HK$398k worth of stock

Price target increased by 11% to HK$8.03

Grand Pharmaceutical Group Limited (HKG:512) Stock Rockets 41% As Investors Are Less Pessimistic Than Expected

Grand Pharmaceutical Group Limited Announces Phase III Study in China of the Group's Global Innovative RDC TLX591-CDx Completes Patient Enrollment and Dosing to Be Submitted This Year

Grand Pharma's Global Innovative Product STC3141 Successfully Reached the Clinical Endpoint in the Phase II Clinical Study in China

Investor sentiment improves as stock rises 19%

The Group's First Generic Fluticasone Propionate Nasal Spray in China Approved for Commercialization

Grand Pharmaceutical Group Limited Announces the Investigator-Initiated Clinical Study Conducted in China of GPN02006

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024

Upcoming dividend of HK$0.26 per share

Grand Pharmaceutical Group Limited's (HKG:512) CEO Compensation Looks Acceptable To Us And Here's Why

Executive Chairman recently bought HK$413k worth of stock

Additional Considerations Required While Assessing Grand Pharmaceutical Group's (HKG:512) Strong Earnings

Grand Pharmaceutical Group Limited Completes First Patient Enrolment and Dosing for International Multi-Center Phase III Clinical Trial in China of the Innovative RDC Product ITM-11

Price target increased by 9.1% to HK$7.23

Grand Pharmaceutical Group Limited, Annual General Meeting, Apr 10, 2025

Full year 2024 earnings: EPS exceeds analyst expectations

Grand Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2024, Payable on 30 April 2025

Grand Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 12, 2025

Little Excitement Around Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China

Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?